Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects

Trial Profile

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2015

At a glance

  • Drugs Cerlapirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 10 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jan 2009 Status changed from not yet recruiting to recruiting s reported by ClinicalTrials.gov.
    • 20 Jan 2009 Actual initiation date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top